Revive Therapeutics (RVV) AI Stock Analysis

• Market Cap: C$4.19M
• Dividend Yield: N/A
• Average Volume (3M): 285.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.71
• Revenue Growth: N/A
• EPS Growth: -80.42%
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 418,564,270
• 10 Day Avg. Volume: 295,136
• 30 Day Avg. Volume: 285,498
• PEG Ratio: >-0.01
• Price to Book (P/B): -2.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: C$0.01 ▲(0.00% Upside)

Score is held down primarily by weak financial fundamentals (no revenue, ongoing losses/cash burn, and a significantly weakened balance sheet with negative equity and reduced assets). Technicals also remain soft with the stock trading below major moving averages and a negative MACD. Valuation provides little support given a negative P/E and no dividend yield.

Positive Factors

Pipeline Focus / Therapeutic Niche

A focused pipeline in psychedelic medicines and drug repurposing represents a differentiated R&D strategy with potential to address unmet indications. Over 2–6 months this supports sustained strategic clarity and potential high-impact catalysts if clinical programs progress.

Reduced Cash Burn Trend

Material reduction in cash burn versus earlier multi‑million outflows improves near-term runway and reduces immediate financing pressure. This structural decline in outflows suggests tighter cost discipline and extends time to advance trials before needing significant external capital.

Low Absolute Debt

Very low nominal debt keeps interest and fixed‑charge burdens minimal, preserving flexibility for financing clinical activities. Over a multi‑month horizon this reduces near‑term solvency risk and allows capital‑raising or partnership options without heavy leverage constraints.

Negative Factors

No Revenue / Continued Losses

Being pre‑revenue with substantial trailing losses means the firm is structurally dependent on external financing until commercialization, raising dilution and funding risk. Over 2–6 months this limits self‑funding ability and constrains investment in multiple parallel programs.

Deteriorated Balance Sheet

Negative equity and a sharp fall in assets materially weaken financial flexibility and bargaining power with investors or partners. Structurally, this increases financing cost and reliance on dilutive capital markets, impairing the company’s ability to fund clinical development sustainably.

Very Small Operational Scale

A two‑person team and minimal asset base create execution and operational risk, increasing dependence on contractors, partners, and external labs. Over months this can slow trial progress, complicate program management, and raise costs or delays in advancing clinical candidates.

Revive Therapeutics Business Overview & Revenue Model

Company Description

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

How the Company Makes Money

Revive Therapeutics generates revenue through the development and commercialization of novel therapeutics. The company's revenue model is based on the successful progression of its drug candidates through clinical trials, leading to licensing agreements, partnerships, or sales upon regulatory approval. Key revenue streams include milestone payments from strategic collaborations, licensing fees, and potential royalties from commercialized products. Additionally, Revive collaborates with other pharmaceutical companies and research institutions to enhance its development pipeline, attracting funding and sharing development costs, which further contributes to its earnings.

Revive Therapeutics Financial Statement Overview

Summary

Non-revenue and loss-making with ongoing cash burn (TTM net income about -$10.8M; TTM operating/free cash flow about -$0.44M). Balance sheet has weakened materially with negative equity (about -$3.5M) and a sharp drop in total assets (about $0.25M TTM vs ~$10.6M FY2024), increasing financing risk despite low absolute debt (~$68K).

Income Statement

TTM (Trailing-Twelve-Months) shows no revenue and continued losses, with net income at about -$10.8M and negative gross profit, indicating the company is still in a pre-commercial or non-revenue stage. Losses improved materially versus FY2024 (net loss about -$5.6M) and remain below the much larger losses seen in FY2021–FY2022, but profitability and margin profile are still weak given the lack of revenue base.

Balance Sheet

Leverage is modest in absolute dollars (TTM total debt about $68K), but the balance sheet quality has deteriorated sharply as stockholders’ equity turned negative (about -$3.5M in TTM and FY2025) versus positive equity in FY2024 and earlier. Total assets are also much smaller (about $0.25M TTM vs ~$10.6M in FY2024), reducing financial flexibility and increasing dependence on external funding.

Cash Flow

Cash burn continues: TTM operating cash flow and free cash flow are both about -$0.44M, and FY2025 free cash flow was about -$0.81M. While cash burn is far lower than FY2021–FY2023 levels (multi-million annual outflows), TTM free cash flow declined versus the prior period (negative growth), and the business is not self-funding given persistent negative operating cash flow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-170.00	-248.00	-328.00	-434.00	-578.00	-775.00
EBITDA	-10.82M	-11.01M	-5.60M	-5.52M	-17.74M	-18.57M
Net Income	-10.82M	-11.01M	-5.62M	-6.32M	-17.83M	-20.20M
Balance Sheet
Total Assets	249.81K	205.02K	10.64M	14.25M	17.07M	29.81M
Cash, Cash Equivalents and Short-Term Investments	30.95K	24.56K	773.07K	2.09M	3.92M	16.60M
Total Debt	68.18K	66.87K	25.22K	219.69K	327.73K	415.84K
Total Liabilities	3.75M	3.66M	3.40M	3.60M	4.46M	999.68K
Stockholders Equity	-3.50M	-3.46M	7.23M	10.65M	12.60M	28.81M
Cash Flow
Free Cash Flow	-440.00K	-807.66K	-3.29M	-6.03M	-13.06M	-11.31M
Operating Cash Flow	-440.00K	-807.66K	-3.29M	-6.03M	-13.06M	-8.31M
Investing Cash Flow	0.00	-30.00K	0.00	0.00	0.00	-2.72M
Financing Cash Flow	187.95K	39.15K	1.98M	4.20M	376.35K	26.24M

Revive Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVV, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.23 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RVV.

Revive Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RAMM	45 Neutral	C$4.18M	-0.32	-69.77%	―	-15.51%	-49.26%
PCLO	44 Neutral	C$12.31M	-2.23	―	―	15.64%	58.47%
MVMD	42 Neutral	C$5.29M	-0.71	-148.48%	―	-46.59%	8.26%
RVV	40 Underperform	C$4.19M	-0.39	-664.21%	―	―	-80.42%
AYUR	40 Underperform	C$973.52K	-0.67	-271.33%	―	15.95%	-1.81%

Revive Therapeutics Corporate Events

Revive Therapeutics Updates on Nerve Agent Countermeasure Study

Revive Therapeutics has announced an update on its research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in collaboration with Defence R&D Canada. The study is expected to conclude in January 2026, with findings to be released upon authorization from DRDC. This collaboration highlights Revive’s strategic focus on developing medical countermeasures and could enhance its positioning in the life sciences industry.

Revive Therapeutics Updates on Nerve Agent Countermeasure Study

Revive Therapeutics announced an update on its ongoing study of Bucillamine as a potential treatment for nerve agent exposure, conducted in collaboration with Defence R&D Canada. The study is still in progress, and the final findings will be released with DRDC’s authorization. This research could strengthen Revive’s position in developing medical countermeasures, potentially impacting stakeholders interested in innovative treatments for nerve agent-induced injuries.